DRAFT 1 Company Contact: Investor Relations Contact: Senesco Technologies, Inc. Lippert/Heilshorn & Associates, Inc. Jack Van Hulst Anne Marie Fields Chief Executive Officer ( afields@lhai.com ) (jvanhulst@senesco.com) (

TECHNOLOGIES REPORTS NYSE AMEX RESCINDS PREVIOUS

LETTER REGARDING SHAREHOLDER MEETING

Meeting of Shareholders Scheduled for May 25, 2010

NEW BRUNSWICK, N.J. (May 5,

2010) -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE

Amex: SNT) today announced that the Company received notification from the NYSE

Amex (the "Exchange"), that, upon further review of the facts, the Exchange was

rescinding a previously issued deficiency letter regarding the Company's Annual

Meeting of Shareholders for 2009.

Company will be hosting its Annual Meeting of Shareholders on May 25, 2010 at

10:00 a.m. at the law offices of Morgan, Lewis and Bockius LLP, 101 Park Avenue,

connection with the holding of the annual meeting, the Company has prepared a

proxy statement for the Company's shareholders which was filed with the SEC on

April 26, 2010. The proxy statement contains information about the Company, the

annual meeting and related matters. SHAREHOLDERS ARE URGED TO READ THE PROXY

STATEMENT CAREFULLY, AS IT CONTAINS IMPORTANT INFORMATION THAT SHAREHOLDERS

SHOULD CONSIDER BEFORE MAKING A DECISION ABOUT APPROVING THE MATTERS TO BE VOTED

UPON AT THE ANNUAL MEETING.

addition to receiving the proxy statement from the Company by mail, shareholders

are able to obtain the proxy statement, as well as other filings containing

information about the Company, without charge, from the SEC's website (http://www.sec.gov )

or, without charge, from the Company's website at www.senesco.com or

by directing such request to Senesco Technologies, Inc. 303 George

St., Suite 420, New Brunswick, New Jersey 08901 Attention: Joel

Company and its directors and executive officers and other members of management

and employees may be deemed to be participants in the solicitation of proxies.

Information concerning the Company and its directors and executive officers is

set forth in the Company's proxy statement and Annual Report on Form 10-K

previously filed with the SEC.

Senesco Technologies, Inc.

Technologies, Inc. is a U.S. biotechnology company, headquartered in New

Brunswick, NJ. Senesco has initiated preclinical research to trigger

or delay cell death in mammals (apoptosis) to determine if the technology is

applicable in human medicine. Accelerating apoptosis may have applications

to development of cancer treatments. Delaying apoptosis may have

applications to certain diseases inflammatory and ischemic diseases.

Senesco takes its name from the scientific term for the aging of plant cells:

senescence. Delaying cell breakdown in plants extends freshness after

harvesting, while increasing crop yields, plant size and resistance to

environmental stress. The Company believes that its technology can be used

to develop superior strains of crops without any modification other than

delaying natural plant senescence. Senesco has partnered with leading-edge

companies engaged in agricultural biotechnology and earns research and

development fees for applying its gene-regulating platform technology to enhance

its partners' products.

statements included in this press release are forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of

1995. Actual results could differ materially from such statements

expressed or implied herein as a result of a variety of factors, including, but

not limited to: the ability of the Company to consummate additional financings;

the development of the Company's gene technology; the approval of the Company's

patent applications; the successful implementation of the Company's research and

development programs and joint ventures; the success of the Company's license

agreements; the acceptance by the market of the Company's products; success of

the Company's preliminary studies and preclinical research; competition and the

timing of projects and trends in future operating performance, the Company's

ability to meet its funding milestones under its financing transaction, the

Company's ability to continue to comply with the continued listing standards of

the AMEX, as well as other factors expressed from time to time in the Company's

periodic filings with the Securities and Exchange Commission (the

"SEC"). As a result, this press release should be read in conjunction

with the Company's periodic filings with the SEC. The forward-looking

statements contained herein are made only as of the date of this press release,

and the Company undertakes no obligation to publicly update such forward-looking

statements to reflect subsequent events or